Eli Lilly reported that its experimental drug retatrutide produced greater average weight reduction than existing obesity treatments in a phase-three study. Participants receiving the highest dose lost an average of 28.3 percent of their body weight over 80 weeks. The trial involved 2,339 adults with obesity or overweight conditions plus at least one related health issue and no diabetes. Patients were assigned to receive one of three doses or a placebo. Those on the 12-milligram dose achieved the largest loss, averaging 70.3 pounds, while the 9-milligram group lost 64.4 pounds and the 4-milligram group lost 47.2 pounds. Nearly two-thirds of participants on the top dose lowered their body-mass index below the obesity threshold. Retatrutide acts on three hormone pathways, including glucagon, which distinguishes it from current GLP-1 medications such as Zepbound and Wegovy. Side effects such as nausea, diarrhea, constipation, and vomiting occurred more frequently with higher doses than with placebo. Researchers also noted improvements in cardiovascular risk markers including cholesterol levels and blood pressure. The findings suggest retatrutide may offer a new option for substantial weight management, though long-term safety data are still being collected.
